Ocular Therapeutix Inc
NASDAQ:OCUL
Intrinsic Value
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. [ Read More ]
The intrinsic value of one OCUL stock under the Base Case scenario is 2.28 USD. Compared to the current market price of 4.74 USD, Ocular Therapeutix Inc is Overvalued by 52%.
Valuation Backtest
Ocular Therapeutix Inc
Run backtest to discover the historical profit from buying and selling OCUL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ocular Therapeutix Inc
Current Assets | 232.2m |
Cash & Short-Term Investments | 195.8m |
Receivables | 26.2m |
Other Current Assets | 10.2m |
Non-Current Assets | 19.8m |
PP&E | 18.2m |
Other Non-Current Assets | 1.6m |
Current Liabilities | 34.9m |
Accounts Payable | 4.4m |
Accrued Liabilities | 30.3m |
Other Current Liabilities | 255k |
Non-Current Liabilities | 126m |
Long-Term Debt | 74.9m |
Other Non-Current Liabilities | 51.1m |
Earnings Waterfall
Ocular Therapeutix Inc
Revenue
|
58.4m
USD
|
Cost of Revenue
|
-5.3m
USD
|
Gross Profit
|
53.2m
USD
|
Operating Expenses
|
-135.5m
USD
|
Operating Income
|
-82.4m
USD
|
Other Expenses
|
1.6m
USD
|
Net Income
|
-80.7m
USD
|
Free Cash Flow Analysis
Ocular Therapeutix Inc
OCUL Profitability Score
Profitability Due Diligence
Ocular Therapeutix Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Ocular Therapeutix Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
OCUL Solvency Score
Solvency Due Diligence
Ocular Therapeutix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Ocular Therapeutix Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCUL Price Targets Summary
Ocular Therapeutix Inc
According to Wall Street analysts, the average 1-year price target for OCUL is 15.81 USD with a low forecast of 11.11 USD and a high forecast of 25.2 USD.
Ownership
OCUL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OCUL Price
Ocular Therapeutix Inc
Average Annual Return | 71.33% |
Standard Deviation of Annual Returns | 224.49% |
Max Drawdown | -91% |
Market Capitalization | 704.5m USD |
Shares Outstanding | 148 627 008 |
Percentage of Shares Shorted | 10.31% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2014-07-25. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.
Contact
IPO
Employees
Officers
The intrinsic value of one OCUL stock under the Base Case scenario is 2.28 USD.
Compared to the current market price of 4.74 USD, Ocular Therapeutix Inc is Overvalued by 52%.